State Street Holds 4.5% Of 4D Molecular Therapeutics Without Seeking Control
The institutional holder reported 2,469,425 common shares in a disclosure covering September 30, 2026.
State Street reported a 4.5% stake in 4D Molecular Therapeutics, which develops genetic medicines, in a passive ownership disclosure filed Tuesday. The holding covered 2,469,425 common shares as of September 30, 2026, and State Street certified that it was not seeking to change or influence the company's control.
Shared Authority Over The Holding
State Street reported shared voting authority for 2,416,070 shares and shared power to dispose of all 2,469,425 shares. It reported no sole voting or disposal authority.
The securities were bought and held as part of routine business, State Street certified. The disclosure also named SSGA Funds Management, State Street Global Advisors Europe and State Street Global Advisors Trust Company.
Retina And Lung Medicines In Development
4D Molecular Therapeutics has no marketed products. Its business centers on engineered adeno-associated viruses—viral carriers used to deliver genetic medicines—with programs targeting the retina and lungs, according to its annual report for the fiscal year ended December 31, 2025.
Its lead candidate, 4D-150, is in late-stage trials for wet age-related macular degeneration, and the company plans a late-stage trial for diabetic macular edema. The cystic fibrosis candidate 4D-710 is in a mid-stage trial supported by funding and collaboration from the Cystic Fibrosis Foundation.
The company is also developing 4D-725 for alpha-1 antitrypsin deficiency lung disease at the preclinical stage. Its discovery platform selects viral carriers in non-human primates to target particular tissues; it produces those carriers internally and through contract manufacturers.
FDMT's market value was $689 million as of 7:22 a.m. ET Tuesday.